The impact of heart failure and bleeding risk on clinical outcomes in patients after percutaneous coronary intervention

心力衰竭和出血风险对经皮冠状动脉介入治疗后患者临床结局的影响

阅读:2

Abstract

BACKGROUND: In recent years, revascularization for ischaemic heart failure (HF) has received increasing attention, and percutaneous coronary intervention (PCI) has been positioned as a high-risk procedure. However, the risk of major bleeding and major adverse cardiac and cerebrovascular events (MACCE) after PCI for patients with ischaemic HF has not been adequately evaluated. METHODS: HF patients were selected from the PENDULUM (Platelet rEactivity in patieNts with DrUg eLUting stent and balancing risk of bleeding and ischaemic event) registry to compare the efficacy and safety of PCI in HF and non-HF patients. In addition, the impact of high bleeding risk (HBR) defined as BARC 3 and 5 was evaluated in these patients. RESULTS: A total of 6266 patients were included; 16% (n = 1006) had a history of HF at enrolment. Patients with HF showed a higher MACCE rate than those without HF (18.4% versus 7.7%; adjusted hazard ratio [HR] = 1.59, 95%CI, 1.30–1.93; p < 0.001) and a significant difference in major bleeding (9.3% versus 3.3%; adjusted HR = 1.74, 95%CI, 1.30–2.33; p < 0.001). HBR was significantly more associated with the MACCE and major bleeding rates than non-HBR, regardless of HF status (adjusted HR = 2.93, 95% CI: 2.33–3.69, p < 0.001, p for interaction = 0.913, adjusted HR = 2.67, 95% CI: 1.89–3.76, p < 0.001, p for interaction = 0.465, respectively). CONCLUSIONS: After contemporary PCI, HF and HBR were independently associated with a higher risk of MACCE and bleeding. HF patients after PCI require more careful management to improve prognosis, particularly with HBR factors. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12872-025-05429-6.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。